Biopsy specimens from 80 cardiac allografts were studied immunocytochemically with nine antibodies selected to identify cellular, immunologic, and vascular aspects of rejection. Results from these experiments were converted to a numeric base and used to calculate rejection indexes for each of these aspects of rejection. Pretransplantation biopsy specimens of donor hearts were studied to determine normal values, and clinical, catheterization, and conventional biopsy findings were used to classify patients as stable or unstable. The standard deviation of cellular and immunologic reaction indexes were overlapping for stable and unstable patients, but the vascular indexes for these patient groups were significantly different, suggesting that vascular damage defines clinical instability in cardiac allograft recipients. To study the vascular index in the absence of cellular infiltrates, biopsy specimens from 80 allografted hearts were selected to represent 40 patients with cellular infiltrates and 40 patients devoid of infiltrates. The results of this analysis revealed no difference in the vascular index between hearts that contained or did not contain infiltrates; the spectrum of vascular damage between the groups ranged from trivial to severe, suggesting that vascular damage was not dependent on cellular infiltrates. Concluding that these were independent events was not possible, however, because none of the hearts continuously were devoid of cellular infiltrates. Two groups of patients with significantly different vascular indexes then were studied for a systemic manifestation of coagulation by measurement of their thrombin times. The group with low vascular index was found to have significantly prolonged thrombin times compared to the group with high vascular index, and a trend to less prolongation of thrombin times was observed in another group with high cellular index. The relation of these results with cardiac allograft vasculopathy is not established, but the results suggest hitherto unexplored roles for quantitative expressions of hemostasis, fibrinolysis, and anticoagulation in the pathophysiology of vascular disease in allografts.
Download full-text PDF |
Source |
---|
Biomark Res
January 2025
Department of Hematology and Medical Oncology, Emory University, 201 Dowman Dr, Atlanta, GA, 30322, USA.
Background: Oncolytic viruses (OVs) are increasingly recognized as promising tools for cancer therapy, as they selectively infect and destroy tumor cells while leaving healthy cells unharmed. Despite considerable progress, the limited therapeutic efficacy of OV-based virotherapy continues to be a significant challenge in cancer treatment.
Methods: The SMAC/DIABLO gene was inserted into the genome of vesicular stomatitis virus (VSV) to generate VSV-S.
Biol Direct
January 2025
School of Medicine, South China University of Technology, Guangzhou, 510006, China.
Background: Pancreatic cancer is characterized by a complex tumor microenvironment that hinders effective immunotherapy. Identifying key factors that regulate the immunosuppressive landscape is crucial for improving treatment strategies.
Methods: We constructed a prognostic and risk assessment model for pancreatic cancer using 101 machine learning algorithms, identifying OSBPL3 as a key gene associated with disease progression and prognosis.
J Orthop Surg Res
January 2025
Department of Hand-Foot Microsurgery, Shenzhen Nanshan People's Hospital, The 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Background: Steroid-induced osteonecrosis of the femoral head (SIONFH) is a universal hip articular disease and is very hard to perceive at an early stage. The understanding of the pathogenesis of SIONFH is still limited, and the identification of efficient diagnostic biomarkers is insufficient. This research aims to recognize and validate the latent exosome-related molecular signature in SIONFH diagnosis by employing bioinformatics to investigate exosome-related mechanisms in SIONFH.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Shandong University School of Medicine, 44 Wenhua Xi Road, Jinan, 250012, Shandong, China.
Introduction: With the increasing impact of hepatocellular carcinoma (HCC) on society, there is an urgent need to propose new HCC diagnostic biomarkers and identification models. Histone lysine lactylation (Kla) affects the prognosis of cancer patients and is an emerging target in cancer treatment. However, the potential of Kla-related genes in HCC is poorly understood.
View Article and Find Full Text PDFClin Transl Oncol
January 2025
Medical Oncology Department, Puerta de Hierro University Hospital, C/ Manuel de Falla, 1, 28222, Majadahonda, Madrid, Spain.
This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T cell receptors, and chimeric antigen receptor T cells, in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma. Several trials are ongoing, and a few have reported results, suggesting that adoptive cell therapies may represent a potential treatment option for these patients, especially when checkpoint inhibition has failed. We also discuss the potential implementation of these therapies, as they present a new toxicity profile and an intrinsic financial burden.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!